Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge
Cosmo Pharmaceuticals (OTC:CMOPF), a global AI-powered healthcare and specialty pharma company, has announced significant progress in its ESG initiatives. The company achieved an MSCI ESG rating upgrade from "BBB" to "A" and saw its LSEG ESG score double to 62.98, ranking #42 globally among peers.
Key developments include becoming a signatory to the UN Global Compact and committing to the Science Based Targets initiative (SBTi) for emissions reduction. These achievements align with Cosmo's Vision 2030 strategy, positioning the company to attract investments from ESG-focused funds, particularly those aligned with SFDR Articles 8 and 9.
Cosmo Pharmaceuticals (OTC:CMOPF), un'azienda globale nel settore sanitario specializzato e farmaceutico potenziata dall'IA, ha annunciato importanti progressi nelle sue iniziative ESG. La società ha ottenuto un upgrade del rating ESG MSCI da "BBB" ad "A" e ha visto il suo punteggio ESG LSEG raddoppiare a 62,98, posizionandosi al #42 a livello globale tra i pari.
Tra gli sviluppi principali vi è la firma del Patto Globale delle Nazioni Unite e l'impegno verso la Science Based Targets initiative (SBTi) per la riduzione delle emissioni. Questi risultati sono in linea con la strategia Vision 2030 di Cosmo, posizionando l'azienda per attrarre investimenti da fondi focalizzati sull'ESG, in particolare quelli conformi agli Articoli 8 e 9 del SFDR.
Cosmo Pharmaceuticals (OTC:CMOPF), una compañía global de salud especializada y farmacéutica impulsada por IA, ha anunciado avances significativos en sus iniciativas ESG. La empresa logró una mejora en la calificación ESG MSCI de "BBB" a "A" y vio cómo su puntuación ESG LSEG se duplicó a 62,98, ubicándose en el puesto #42 a nivel mundial entre sus pares.
Los desarrollos clave incluyen convertirse en firmante del Pacto Mundial de la ONU y comprometerse con la iniciativa Science Based Targets (SBTi) para la reducción de emisiones. Estos logros están alineados con la estrategia Visión 2030 de Cosmo, posicionando a la compañía para atraer inversiones de fondos enfocados en ESG, especialmente aquellos alineados con los Artículos 8 y 9 del SFDR.
코스모 파마슈티컬스(OTC:CMOPF)는 AI 기반의 글로벌 헬스케어 및 전문 제약 회사로서 ESG 이니셔티브에서 중요한 진전을 발표했습니다. 회사는 MSCI ESG 등급을 "BBB"에서 "A"로 상향 조정받았으며, LSEG ESG 점수가 62.98로 두 배 증가해 전 세계 동종 업계에서 42위를 기록했습니다.
주요 발전 사항으로는 유엔 글로벌 콤팩트 서명과 과학 기반 목표 이니셔티브(SBTi)에 대한 배출량 감축 약속이 포함됩니다. 이러한 성과는 코스모의 비전 2030 전략과 일치하며, 특히 SFDR 8조 및 9조에 부합하는 ESG 중심 펀드로부터 투자를 유치할 수 있는 위치를 확보합니다.
Cosmo Pharmaceuticals (OTC:CMOPF), une entreprise mondiale de santé spécialisée et pharmaceutique alimentée par l'IA, a annoncé des progrès significatifs dans ses initiatives ESG. La société a obtenu une amélioration de sa notation ESG MSCI de "BBB" à "A" et a vu son score ESG LSEG doubler pour atteindre 62,98, se classant au 42e rang mondial parmi ses pairs.
Les développements clés incluent la signature du Global Compact des Nations Unies et l'engagement envers l'initiative Science Based Targets (SBTi) pour la réduction des émissions. Ces réalisations s'alignent sur la stratégie Vision 2030 de Cosmo, positionnant l'entreprise pour attirer des investissements de fonds axés sur l'ESG, en particulier ceux conformes aux articles 8 et 9 du SFDR.
Cosmo Pharmaceuticals (OTC:CMOPF), ein globales, KI-gestütztes Gesundheits- und Spezialpharmaunternehmen, hat bedeutende Fortschritte in seinen ESG-Initiativen bekannt gegeben. Das Unternehmen erreichte ein MSCI ESG-Rating-Upgrade von "BBB" auf "A" und verdoppelte seine LSEG ESG-Punktzahl auf 62,98, womit es weltweit auf Platz 42 unter seinen Wettbewerbern liegt.
Wichtige Entwicklungen umfassen die Unterzeichnung des UN Global Compact und das Engagement für die Science Based Targets Initiative (SBTi) zur Emissionsreduzierung. Diese Erfolge stehen im Einklang mit der Vision 2030-Strategie von Cosmo und positionieren das Unternehmen, um Investitionen von ESG-fokussierten Fonds anzuziehen, insbesondere von solchen, die den SFDR-Artikeln 8 und 9 entsprechen.
- MSCI ESG Rating upgraded to 'A' from 'BBB'
- LSEG ESG score doubled to 62.98, ranking #42 globally among peers
- Joined UN Global Compact initiative
- Committed to Science Based Targets initiative (SBTi) for emissions reduction
- Positioned to attract ESG-focused investment funds
- None.
Dublin, Ireland--(Newsfile Corp. - July 16, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact.
In the past year, Cosmo has taken bold steps to embed ESG into the core of its business. This has been delivering measurable results that now place the Company among the top sustainability performers in its industry:
MSCI ESG Rating Upgraded to “A” – Cosmo has advanced from “BBB” to “A”, placing it ahead of many mid-cap peers globally. The upgrade recognizes Cosmo’s tangible progress on carbon emissions, workforce engagement, and board-level governance.
LSEG ESG Score Doubled – Now Ranked #42 Globally in the peer group. With its score rising from 31.31 to 62.98, Cosmo has broken into the top 100 for the first time, signalling growing investor confidence and ESG credibility.
Signatory to the United Nations Global Compact – Cosmo has joined the world’s largest corporate sustainability initiative, aligning its strategy with the UN’s Ten Principles on human rights, labour, environment, and anti-corruption.
Formal Commitment to the Science Based Targets initiative (SBTi) – In a decisive move toward climate accountability, Cosmo has pledged to set science-based emissions reduction targets in line with the Paris Agreement.
Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented: “Cosmo is evolving into a new kind of healthcare company, where scientific innovation, operational excellence, and environmental stewardship are inseparable. These milestones are not checkboxes; they are foundational to our long-range ambition. ESG is not a side initiative – it is core to building a high-performance, future-ready business. We’re proud of the progress, and even more determined to lead with discipline, transparency, and speed.”
Niall Donnelly, EVP Corporate Governance and Chief Sustainability Officer, added: “These upgrades reflect years of internal work to make ESG part of how we think, decide, and operate. The journey doesn’t end here. Our SBTi commitment and UN Compact engagement show we are not just signalling intent. We are taking action that is measurable, science-aligned, and investor-relevant.”
These achievements build on Cosmo’s Vision 2030 strategy, which places ESG at the intersection of innovation and execution. As sustainability becomes a defining metric for healthcare investors, Cosmo is positioned to capture growing capital inflows from Article 8 and Article 9 SFDR-aligned funds and other ESG-driven portfolios.
The Company’s latest ESG Report, performance metrics, and future goals can be accessed at: https://www.cosmopharma.com/company/sustainability.
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy).
For more information, visit www.cosmohealthconfidence.com
Financial calendar
| Half-Year 2025 Results and Report | July 23, 2025 |
For further information, please contact:
investor.relations@cosmohc.com
Attachments
PDF - English
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258996
FAQ
What is Cosmo Pharmaceuticals' (CMOPF) new MSCI ESG rating in 2025?
What is Cosmo's current LSEG ESG score and ranking?
What major sustainability commitments has CMOPF made in 2025?
How will Cosmo's ESG improvements affect its investment potential?
